Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross TN Durvalumab Prior Auth | OpenPayer
    Ask Trek AI about this page
    DraftBlue Cross Blue Shield of TennesseePolicy ID_CHS_18202026c_1026

    Durvalumab (Imfinzi®)

    Customize your policy alerts

    Sign up for blue cross blue shield - tennessee Policy ID_CHS_18202026c_1026 alerts

    Get alerted when Policy ID_CHS_18202026c_1026 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and prior authorization for durvalumab (Imfinzi) for FDA-approved and specified compendial cancer indications. Coverage requires that applicable approval criteria are met and that the member has no exclusion to the prescribed therapy.

    Policy Summary
    PayerBlue Cross Blue Shield of Tennessee
    PolicyDurvalumab (Imfinzi®)
    Policy CodePolicy ID_CHS_18202026c_1026
    Change TypeNo material clinical or coverage change
    Effective DateDec 31, 202642d
    Next Review DateN/A
    Key ActionSubmit documentation supporting the applicable FDA-approved or compendial indication and all applicable approval criteria, including molecular, tumor-status, and PD-L1 documentation when applicable.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    7FDA-approved indication categories identified
    12Compendial-use disease categories identified
    6 monthsStandard authorization period
    1Explicit coverage exclusion

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    >50 mut/Mb
    Ultra-hypermutated TMB threshold

    Coverage Criteria

    Covered FDA-approved and compendial indications

    Covered when the requested use is an FDA-approved indication or listed compendial use, all applicable approval criteria are met, and no exclusion applies.

    General coverage requirements

    • Covered disease indication: Durvalumab is requested for one of the FDA-approved or compendial disease indications listed in this policy.

    NSCLC initial therapy

    Covered for NSCLC when any one of the following criteria groups is met.

    NSCLC initial therapy: Unresectable stage II or III NSCLC that has not progressed following concurrent platinum-based chemotherapy and radiation therapy, with EGFR exon 19 deletion and exon 21 L858R mutation-negative tumor unless testing is infeasible because of insufficient tissue, and durvalumab used as a single agent; OR recurrent, advanced, or metastatic NSCLC negative for EGFR exon 19 deletion and exon 21 L858R mutations and ALK, RET, and ROS1 gene fusions unless testing is infeasible because of insufficient tissue, with durvalumab used with tremelimumab-actl plus platinum-based chemotherapy or as single-agent or pemetrexed-combination maintenance; OR resectable NSCLC treated with durvalumab neoadjuvantly with platinum-containing chemotherapy and continued after surgery as a single agent, with EGFR exon 19 deletion and exon 21 L858R mutation-negative and ALK, RET, and ROS1 fusion-negative tumor unless testing is infeasible because of insufficient tissue.

    Small cell lung cancer

    Covered for SCLC when any one of the following criteria is met.

    SCLC treatment: First-line extensive-stage SCLC with etoposide and carboplatin or cisplatin followed by single-agent maintenance; OR adjuvant consolidation for limited-stage SCLC as a single agent when there was no disease progression after systemic therapy with concurrent radiation therapy; OR subsequent therapy for progression or relapse with etoposide and carboplatin or cisplatin followed by single-agent maintenance.

    Biliary tract cancer

    Covered for biliary tract cancer in the specified treatment settings.

    Biliary tract cancer: Locally advanced, unresectable, gross residual (R2), or metastatic biliary tract cancer treated with cisplatin or carboplatin plus gemcitabine; OR adjuvant biliary tract cancer treatment with cisplatin or carboplatin plus gemcitabine; OR resectable locoregionally advanced gallbladder cancer treated neoadjuvantly with cisplatin or carboplatin plus gemcitabine.

    Hepatocellular carcinoma

    Covered for hepatocellular carcinoma when the applicable first-line or subsequent-treatment criteria are met.

    Hepatocellular carcinoma: First-line unresectable or extrahepatic/metastatic hepatocellular carcinoma in a member ineligible for transplant, with durvalumab as a single agent or with tremelimumab-actl; OR subsequent treatment of unresectable or extrahepatic/metastatic hepatocellular carcinoma with durvalumab as a single agent, or with tremelimumab-actl when the member has not previously received an anti-CTLA4-based regimen.

    Endometrial carcinoma

    Covered when all criteria are met.

    Endometrial carcinoma: Advanced or recurrent endometrial carcinoma with a dMMR tumor; and durvalumab used with carboplatin and paclitaxel followed by single-agent durvalumab.

    Bladder cancer

    Covered for either specified bladder cancer setting.

    Bladder cancer: Perioperative or sandwich treatment of stage II or IIIA bladder cancer with gemcitabine and cisplatin before cystectomy followed by single-agent therapy after surgery; OR BCG-naïve, high-risk nonmuscle invasive bladder cancer treated with durvalumab in combination with BCG.

    Gastric, GEJ, and esophageal adenocarcinoma

    Covered when the applicable criteria are met.

    Gastric, GEJ, or esophageal adenocarcinoma that is MSI-H or dMMR in a member medically fit for surgery, with durvalumab plus tremelimumab-actl for neoadjuvant treatment; OR perioperative treatment with FLOT for a tumor with PD-L1 ≥ 1 or a clinically node-negative tumor.PD-L1 ≥ 1 for one eligibility pathway

    Ampullary adenocarcinoma

    Covered when both criteria are met.

    Ampullary adenocarcinoma: First-line metastatic ampullary adenocarcinoma that is pancreatobiliary or mixed type and treated with cisplatin plus gemcitabine.

    Cervical cancer

    Covered for the specified cervical cancer treatment.

    Cervical cancer: Persistent, recurrent, or metastatic small cell neuroendocrine carcinoma of the cervix treated with etoposide and cisplatin or carboplatin followed by single-agent maintenance therapy.

    Colorectal adenocarcinoma

    Covered when all criteria are met.

    Colorectal adenocarcinoma: Resectable, locally unresectable, medically inoperable, or metastatic colorectal adenocarcinoma with dMMR/MSI-H tumor or POLE/POLD1 mutation with an ultra-hypermutated phenotype and TMB greater than 50 mut/Mb; and durvalumab used as a single agent.TMB > 50 mut/Mb for POLE/POLD1 pathway

    Pleural mesothelioma

    Covered for first-line treatment.

    Pleural mesothelioma: Unresectable pleural mesothelioma treated first line with durvalumab plus pemetrexed and cisplatin or carboplatin.

    Small bowel adenocarcinoma

    Covered when all criteria are met.

    Small bowel adenocarcinoma: Resectable, locally unresectable, medically inoperable, advanced, or metastatic small bowel adenocarcinoma with dMMR/MSI-H tumor or POLE/POLD1 mutation with an ultra-hypermutated phenotype and TMB greater than 50 mut/Mb; and durvalumab used as a single agent.TMB > 50 mut/Mb for POLE/POLD1 pathway

    NSCLC continuation therapy

    Covered for NSCLC reauthorization when any one of the following criteria is met.

    NSCLC continuation therapy: Unresectable stage II or III NSCLC without unacceptable toxicity or disease progression on the current regimen, up to 12 months total; OR recurrent, advanced, or metastatic NSCLC without unacceptable toxicity or disease progression on the current regimen; OR resectable NSCLC without unacceptable toxicity or disease progression on the current regimen, up to 12 cycles after surgery.

    NSCLC continuation therapy

    Continued NSCLC treatment may be authorized for 6 months when any one of the following criteria is met.

    NSCLC continuation

    • Unresectable stage II or III NSCLC with no unacceptable toxicity or disease progression on the current regimen.Up to 12 months total
    • Recurrent, advanced, or metastatic NSCLC with no unacceptable toxicity or disease progression on the current regimen.
    • Resectable NSCLC with no unacceptable toxicity or disease progression on the current regimen.Up to 12 cycles after surgery

    Limited-stage SCLC continuation therapy

    Continued limited-stage SCLC treatment may be authorized for 6 months.

    Limited-stage SCLC continuation: Limited-stage SCLC with no unacceptable toxicity or disease progression while on the current regimen.Up to 24 months total

    Gastric, GEJ, and esophageal adenocarcinoma continuation

    Gastric, GEJ, or esophageal adenocarcinoma treatment has separate neoadjuvant and perioperative continuation pathways.

    Continuation pathway

    • Neoadjuvant treatment of gastric, gastroesophageal junction, or esophageal adenocarcinoma used in combination with tremelimumab-actl (Imjudo).3 months; total of 3 doses

      Reauthorization is permitted only when the member did not receive all 3 doses from the initial approval.

    • Perioperative continuation: Continued perioperative treatment for gastric, gastroesophageal junction, or esophageal adenocarcinoma with no unacceptable toxicity, disease progression, or recurrence while on the current regimen.Up to 12 cycles after surgery

    Bladder cancer continuation therapy

    Continued bladder cancer treatment may be authorized for 6 months under either listed pathway.

    Bladder cancer continuation

    • Perioperative or sandwich treatment: Continued perioperative or sandwich treatment of bladder cancer with no unacceptable toxicity or disease progression while on the current regimen.Up to 12 cycles
    • BCG-naïve high-risk non-muscle-invasive bladder cancer: BCG-naïve, high-risk non-muscle-invasive bladder cancer with no unacceptable toxicity or disease progression while on the current regimen.Up to 13 cycles

    Other-indication continuation therapy

    Continued treatment for other indications listed in the coverage criteria may be authorized for 6 months.

    All other listed indications: The member is receiving treatment for an indication listed in the coverage criteria and has no unacceptable toxicity or disease progression while on the current regimen.6-month authorization

    Coverage is excluded for members who have experienced disease progression while receiving PD-1 or PD-L1 inhibitor therapy.

    Uses of durvalumab that are not among the policy’s listed FDA-approved or compendial indications are considered experimental or investigational and not medically necessary.

    Biomarker and Coding Reference

    Ultra-hypermutated tumor mutational burden
    BiomarkerPOLE/POLD1 with ultra-hypermutated tumor status
    TMB threshold>50 mutations/megabase (mut/Mb)
    DocumentationLaboratory report confirming the tumor status, where applicable
    Tumor PD-L1 expression
    BiomarkerTumor PD-L1 expression
    Threshold≥ 1
    Applicable settingPerioperative gastric, GEJ, or esophageal adenocarcinoma pathway

    Authorization and Documentation Requirements

    Documentation Required

    Submit Indication and Biomarker Documentation

    Submit the requested indication, clinical setting, regimen, and applicable biomarker documentation with the prior authorization request. Coverage is available only when all applicable approval criteria are met and no exclusion applies.

    • Document the applicable diagnosis and treatment setting.
    • Submit required laboratory and biomarker reports, including molecular testing where applicable.
    • Document the requested regimen and treatment line.
    Prior Authorization

    Disease-Specific Prior Authorization Required

    Prior authorization is required for the listed disease-specific indications. The standard authorization period is 6 months unless a shorter or dose-limited period is specified.

    Policy Background

    Durvalumab (Imfinzi) is an immune checkpoint inhibitor used across multiple solid-tumor settings, including lung, biliary tract, liver, gynecologic, bladder, gastric or gastroesophageal junction, and other cancers. The policy addresses specified FDA-approved and compendial uses, often in combination with chemotherapy, radiation, surgery, tremelimumab-actl, Bacillus Calmette-Guérin, or other oncology agents.

    Definitions

    MSI-H
    TermMSI-H
    DefinitionA tumor characterized by high microsatellite instability
    DocumentationLaboratory confirmation may be required where applicable
    dMMR
    TermdMMR
    DefinitionA tumor with deficient mismatch repair
    DocumentationLaboratory confirmation may be required where applicable

    Initial Therapy Criteria

    Initial therapy by indication

    Initial authorization is generally granted for 6 months when the applicable disease-specific criteria are met.

    Disease-specific initial therapy: The member must have one of the covered diagnoses and treatment settings specified in the policy, and the requested durvalumab regimen must use the required partner drugs, biomarker selection, disease stage, prior therapy, or treatment sequence for that diagnosis.

    Continuation Therapy Criteria

    NSCLC continuation

    Authorization of 6 months may be granted for continued NSCLC treatment when any criterion below is met.

    NSCLC reauthorization: Unresectable stage II or III NSCLC with no unacceptable toxicity or disease progression on the current regimen, up to 12 months total; OR recurrent, advanced, or metastatic NSCLC with no unacceptable toxicity or disease progression on the current regimen; OR resectable NSCLC with no unacceptable toxicity or disease progression on the current regimen, up to 12 cycles after surgery.

    NSCLC

    Authorization of 6 months may be granted for continued NSCLC treatment when any listed pathway is met.

    NSCLC continuation: Unresectable stage II or III NSCLC, recurrent, advanced, or metastatic NSCLC, or resectable NSCLC, with no unacceptable toxicity or disease progression on the current regimen.Up to 12 months total for unresectable stage II or III disease; up to 12 cycles after surgery for resectable disease

    Dosing and Quantity Limits

    Durvalumab quantity limit
    DrugDurvalumab
    Authorization period3 months
    Quantity limitTotal of 3 doses for the neoadjuvant regimen
    Imfinzi (durvalumab) dosing schedule
    RouteIntravenous
    Patients ≥30 kg1,500 mg every 3 weeks for up to 8 cycles, then 1,500 mg every 4 weeks
    Patients <30 kg20 mg/kg every 3 weeks for up to 8 cycles, then 20 mg/kg every 4 weeks
    Policy Summary
    PayerBlue Cross Blue Shield of Tennessee
    PolicyDurvalumab (Imfinzi®)
    Policy CodePolicy ID_CHS_18202026c_1026
    Change TypeNo material clinical or coverage change
    Effective DateDec 31, 202642d
    Next Review DateN/A
    Key ActionSubmit documentation supporting the applicable FDA-approved or compendial indication and all applicable approval criteria, including molecular, tumor-status, and PD-L1 documentation when applicable.
    SourceLink
    On This Page
    Coverage CriteriaBiomarker and Coding ReferenceAuthorization and Documentation RequirementsPolicy BackgroundDefinitionsInitial Therapy CriteriaContinuation Therapy CriteriaDosing and Quantity Limits
    POLE/POLD1 tumor mutational burden
    BiomarkerPOLE/POLD1 mutation with an ultra-hypermutated phenotype
    TMB threshold> 50 mut/Mb
    Applicable diseasesColorectal or small bowel adenocarcinoma
  1. NSCLC, SCLC, biliary tract cancer, hepatocellular carcinoma, endometrial carcinoma, bladder cancer, gastric/GEJ/esophageal adenocarcinoma, ampullary adenocarcinoma, cervical cancer, colorectal adenocarcinoma, pleural mesothelioma, and small bowel adenocarcinoma are listed indications.
  2. Gastric, GEJ, or esophageal adenocarcinoma neoadjuvant therapy may be authorized for 3 months and 3 total doses.
  3. All other listed indication authorizations are generally for 6 months.
  4. Prior Authorization

    Reauthorization Requires Continued Eligibility

    For reauthorization, document the diagnosis, current treatment setting and regimen, clinical response or continued eligibility, and absence of progression or unacceptable toxicity. Apply the indication-specific treatment limits.

    • NSCLC: authorization may continue up to 12 months for unresectable stage II/III disease or up to 12 cycles after surgery for resectable disease.
    • Limited-stage SCLC: authorization may continue up to 24 months total.
    • Gastric, GEJ, or esophageal adenocarcinoma: continued perioperative therapy may continue up to 12 cycles after surgery.
    • Bladder cancer: continued therapy may continue up to 12 cycles for perioperative/sandwich treatment or up to 13 cycles for BCG-naïve high-risk NMIBC.
    • Other listed indications require ongoing eligibility with no unacceptable toxicity or disease progression.
    Documentation Required

    Tennessee Off-Label Indication Recognition

    For an off-label use of an FDA-approved drug, document that the requested use is recognized under Tennessee requirements by a statutorily recognized standard reference compendium or published peer-reviewed medical literature.

    • Apply Tennessee Code Annotated Section 56-7-2352.
    • Include the applicable compendium citation or peer-reviewed literature supporting the requested off-label indication.
    Documentation Required

    Document EGFR Mutation Status

    Where required by the applicable indication, submit testing documenting that the tumor is negative for EGFR exon 19 deletion and exon 21 L858R mutations. Testing may be considered infeasible when tissue is insufficient.

    • Document absence of EGFR exon 19 deletion and exon 21 L858R mutations.
    • If testing is not feasible because of insufficient tissue, document the reason.
    Documentation Required

    Document Gene Fusion Status

    Where required, submit documentation showing absence of ALK, RET, and ROS1 gene fusions. If testing cannot be completed because tissue is insufficient, document that limitation.

    • Provide the applicable ALK, RET, and ROS1 molecular testing results.
    • For recurrent, advanced, or metastatic NSCLC and resectable NSCLC, document negative fusion status or insufficient tissue preventing testing.
    Documentation Required

    Submit Tumor Biomarker Results

    Submit laboratory evidence of the applicable tumor biomarker status when the requested indication requires it.

    • Provide a report confirming MSI-H or dMMR status where applicable.
    • Provide POLE/POLD1 mutation results with an ultra-hypermutated tumor mutational burden greater than 50 mutations per megabase (mut/Mb), where applicable.
    • Biomarker documentation is relevant to endometrial, gastric/GEJ/esophageal, colorectal, and small bowel adenocarcinoma criteria.
    Documentation Required

    Document PD-L1 Expression

    Submit tumor PD-L1 expression documentation when applicable to the requested indication and regimen.

    • Provide the tumor PD-L1 laboratory or pathology report.
    • For perioperative gastric, GEJ, or esophageal adenocarcinoma with FLOT, document PD-L1 expression of at least 1 when relying on that criterion.
    Documentation Required

    NSCLC Molecular Testing Required

    For NSCLC requests, document applicable molecular testing for EGFR exon 19 deletion and exon 21 L858R mutations and ALK, RET, and ROS1 gene fusions. If testing is not feasible because of insufficient tissue, document that circumstance.

    • For unresectable stage II/III NSCLC, document EGFR-negative status or insufficient tissue.
    • For recurrent, advanced, or metastatic NSCLC, document negative EGFR and ALK/RET/ROS1 fusion status or insufficient tissue.
    • For resectable NSCLC, document negative EGFR and ALK/RET/ROS1 fusion status or insufficient tissue.
    Documentation Required

    Document Hepatocellular Carcinoma Eligibility

    For hepatocellular carcinoma, document that the disease is unresectable or extrahepatic/metastatic and, for first-line treatment, that the member is ineligible for transplant.

    • First-line therapy may be single-agent durvalumab or durvalumab with tremelimumab-actl.
    • For subsequent therapy, document single-agent use or combination with tremelimumab-actl when the member has not previously received an anti-CTLA4-based regimen.
    Documentation Required

    Submit Biomarker and Staging Documentation

    Submit the applicable biomarker, tumor mutational burden, and disease-setting documentation for indications with biomarker or staging requirements.

    • Endometrial carcinoma: document dMMR status and the required carboplatin/paclitaxel regimen followed by single-agent therapy.
    • Gastric/GEJ/esophageal adenocarcinoma: document MSI-H or dMMR status, surgical fitness, and the required neoadjuvant or perioperative setting.
    • Colorectal and small bowel adenocarcinoma: document dMMR/MSI-H or POLE/POLD1 ultra-hypermutated phenotype with TMB greater than 50 mut/Mb and single-agent use.
    Denial Risk

    Identify Unlisted Indications

    Identify requested uses that are not among the policy's listed FDA-approved or compendial indications. Such uses are considered experimental or investigational and not medically necessary unless they qualify under Tennessee's off-label mandate requirements.

    • List the requested diagnosis and intended use when it does not appear among the covered compendial uses.
    • For eligible Tennessee off-label requests, provide recognized compendium or peer-reviewed literature support.
    Denial Risk

    Progression on PD-1 or PD-L1 Therapy

    Coverage is excluded when the member has experienced disease progression while receiving PD-1 or PD-L1 inhibitor therapy.

    • Review prior immunotherapy history before submission.
    • Document that the requested therapy is not being sought after progression on PD-1 or PD-L1 inhibitor therapy.
    Denial Risk

    All Approval Criteria Must Be Met

    Coverage requires satisfaction of every applicable approval criterion and the absence of applicable exclusions. A request that does not meet the criteria or has an applicable exclusion is at risk for denial.

    • Confirm the indication is listed or qualifies under the Tennessee off-label mandate.
    • Confirm required diagnosis, disease extent, treatment line, regimen, biomarkers, and molecular testing.
    • Confirm no progression on PD-1 or PD-L1 inhibitor therapy.
    Denial Risk

    Failure to Meet Indication-Specific Criteria

    Requests may be denied when indication-specific requirements are not satisfied, including disease setting, biomarker or molecular status, treatment line, required combination regimen, or specified maintenance or perioperative sequence.

    • Use only the regimen and treatment sequence specified for the applicable indication.
    • Document required disease extent, staging, transplant eligibility, surgical fitness, and biomarker status.
    • Confirm required combinations, including chemotherapy, radiation, BCG, tremelimumab-actl, or maintenance therapy, as applicable.
    Denial Risk

    NSCLC Progression or Unacceptable Toxicity

    Continued NSCLC treatment may be denied when there is evidence of disease progression or unacceptable toxicity on the current regimen, or when the applicable treatment-duration limit has been reached.

    • Document no progression and no unacceptable toxicity.
    • Apply the 12-month total limit for unresectable stage II/III NSCLC and the 12-cycle-after-surgery limit for resectable NSCLC.
    Denial Risk

    Continuation Denial Risks

    Continuation may be denied for progression, unacceptable toxicity, recurrence where the policy requires no recurrence, or completion of the applicable treatment limit.

    • NSCLC and limited-stage SCLC require no progression or unacceptable toxicity.
    • Gastric, GEJ, or esophageal adenocarcinoma requires no progression, unacceptable toxicity, or recurrence for continued perioperative therapy.
    • Bladder cancer and other listed indications require no progression or unacceptable toxicity and compliance with applicable cycle limits.
    Denial Risk

    Complete the Initial Three-Dose Course

    For neoadjuvant gastric, GEJ, or esophageal adenocarcinoma, reauthorization is available only when the member did not receive all 3 doses authorized in the initial 3-dose course.

    • Initial authorization is for 3 months and a total of 3 doses with tremelimumab-actl.
    • Document the number of doses received and the reason the initial 3-dose course was incomplete.
    POLE/POLD1 ultra-hypermutated TMB
    BiomarkerPOLE/POLD1
    PhenotypeUltra-hypermutated tumor mutational burden
    Threshold>50 mutations per megabase
    Extensive-stage SCLC
    DiseaseSmall cell lung cancer
    StageExtensive-stage
    Policy descriptionDisease that has spread extensively
    BCG-naïve high-risk NMIBC
    Cancer typeHigh-risk nonmuscle invasive bladder cancer (NMIBC)
    BCG statusBCG-naïve
    MeaningThe member has not previously received Bacillus Calmette-Guérin
    MSI-H/dMMR
    MSI-HHigh microsatellite instability
    dMMRDeficient mismatch repair
    Combined definitionA tumor with high microsatellite instability or deficient mismatch repair
    POLE/POLD1 ultra-hypermutated phenotype
    MutationPOLE or POLD1 mutation
    PhenotypeUltra-hypermutated
    TMB threshold>50 mutations per megabase
    Unresectable stage II or III NSCLC
    Cancer typeNon-small cell lung cancer (NSCLC)
    StageStage II or III
    ResectabilityCannot be removed surgically
    Limited-stage SCLC
    DiseaseSmall cell lung cancer
    StageLimited stage
    Continuation requirementNo unacceptable toxicity or disease progression on the current regimen
    BCG-naive high-risk non-muscle-invasive bladder cancer
    Cancer typeHigh-risk non-muscle-invasive bladder cancer
    BCG statusBCG-naive
    MeaningThe member has not previously received Bacillus Calmette-Guérin

    Limited-stage SCLC

    Authorization of 6 months may be granted for continued treatment.

    Limited-stage SCLC: No unacceptable toxicity or disease progression while on the current regimen.Up to 24 months total

    Gastric, GEJ, and esophageal adenocarcinoma

    Authorization may be granted for neoadjuvant or continued perioperative treatment.

    Gastric, GEJ, or esophageal adenocarcinoma: Neoadjuvant treatment with tremelimumab-actl or continued perioperative treatment without unacceptable toxicity, disease progression, or recurrence.Neoadjuvant: 3 months and 3 doses; perioperative: up to 12 cycles after surgery

    Neoadjuvant reauthorization only applies if all 3 initial doses were not received.

    Bladder cancer

    Authorization of 6 months may be granted for continued bladder cancer treatment.

    Bladder cancer: Perioperative or sandwich bladder cancer treatment or BCG-naïve high-risk non-muscle-invasive bladder cancer, with no unacceptable toxicity or disease progression on the current regimen.Up to 12 cycles for perioperative/sandwich treatment; up to 13 cycles for BCG-naïve high-risk non-muscle-invasive disease

    All other indications

    Authorization of 6 months may be granted for continued treatment.

    Other listed indications: The indication is listed in the coverage criteria and there is no unacceptable toxicity or disease progression while on the current regimen.6 months
    Imfinzi (durvalumab) dosing schedule
    RouteIntravenous
    Initial regimen, ≥30 kg1,500 mg every 3 weeks for up to 8 cycles
    Maintenance regimen, ≥30 kg1,500 mg every 4 weeks
    Imfinzi (durvalumab) initial and maintenance dosing
    RouteIntravenous
    Initial regimen1,500 mg every 3 weeks for 4 doses
    Maintenance regimen1,500 mg every 4 weeks
    Imfinzi four-cycle regimen
    DrugImfinzi (durvalumab)
    Dose1,500 mg
    ScheduleEvery 3 weeks for 4 cycles, intravenously
    Imfinzi maintenance dosing
    DrugImfinzi
    Dose1,500 mg
    ScheduleEvery 4 weeks intravenously
    Imfinzi weight-based initial and maintenance dosing
    RouteIntravenous
    Patients ≥30 kg initial dose1,120 mg every 3 weeks for 6 doses
    Maintenance dose1,500 mg every 4 weeks
    Durvalumab four-week dosing
    RouteIntravenous
    Patients ≥30 kg1,500 mg every 4 weeks
    Patients <30 kg20 mg/kg every 4 weeks
    Imfinzi dosing by patient weight
    Initial regimen, ≥30 kg1,500 mg every 3 weeks for 4 cycles
    Maintenance regimen, ≥30 kg1,500 mg every 4 weeks
    Patients <30 kg20 mg/kg every 3 weeks for 4 cycles, then 20 mg/kg every 4 weeks
    Imfinzi 1,120-mg regimen
    DrugImfinzi (durvalumab)
    Dose1,120 mg
    Route and scheduleIntravenously every 3 weeks
    Imfinzi initial and maintenance regimen
    Maintenance dose1,500 mg every 4 weeks intravenously
    Patients <30 kg maintenance20 mg/kg every 4 weeks
    Initial regimen for patients <30 kg20 mg/kg every 3 weeks for 4 cycles